Reentrant ventricular tachycardia. Interpretations of electrophysiologic findings and its applications.
Monomorphic sustained ventricular tachycardia (MSVT) was revisited in relation to the electrophysiologic findings and their relation to the drug efficacy. Old myocardial infarction is less common cause of MSVT in Japan, and the majority (about 2/3) of MSVT is unrelated to coronary artery disease but, the mechanism shared a common mechanism: reentry with an excitable gap as others. The reentrant mechanism was supported from the inducibility, the terminability of VT by electrical stimulation, and by the ability to entrain with rapid pacing. In MSVT associated with underlying heart diseases, diseased myocardium showed low amplitude and fragmented electrograms and the area was considered to participate as the central common pathway of reentrant circuit. The area of slow pathway showed a decremental conduction or all-or-nothing conductive property. The width of the excitable gap seemed to be determined by the maximal conductive frequency but not by the duration of action potential: effective refractory period. As to the drug efficacy, there was no baseline characteristics in predicting the efficacy. However, the significant narrowing of the width of the excitable gap was associated with the drug efficacy and VT became non-inducible after addition of the same drug. The response pattern of the excitable gap to specific drug including class III, was not predictable. Further electropharmacological studies will be warranted.
Aizawa
Y
Y
First Department of Internal Medicine, Niigata University School of Medicine, Japan.
Tanabe
Y
Y
Yamaura
M
M
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D009202:Cardiomyopathies / Q000503:physiopathology; D004206:Disopyramide / Q000494:pharmacology; D004562:Electrocardiography; D004594:Electrophysiology; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D008801:Mexiletine / Q000494:pharmacology; D011342:Procainamide / Q000494:pharmacology; D017180:Tachycardia, Ventricular / Q000188:drug therapy / Q000503:physiopathology*
D000889:Anti-Arrhythmia Agents; D007093:Imidazoles; D008801:Mexiletine; D004206:Disopyramide; D011342:Procainamide; C032151:cifenline